

GLYCEMIC TARGETS*			
Functional Status (Clinical Frailty Score) or Category of Patient	A1c Targets (%)	Before Meal (preprandial - ac) Targets (mmol/L)	2 hr. Post Meal (postprandial - pc) Targets (mmol/L)
Adult Functionally Independent (1-3) <ul style="list-style-type: none"> Type 2 DM to reduce risk of CKD (not on insulin or secretagogue) Most adults with type 1 or 2 diabetes Recurrent severe hypoglycemia or hypoglycemia unawareness 	≤ 6.5 ≤ 7 7.1–8.5	4–7 (4–5.5 if meet preprandial targets, A1c > 7% & safe) 6–9	5–10 (5–8 if meet preprandial targets, A1c > 7% & safe) < 14
Adult Functionally Dependent (4-5) <ul style="list-style-type: none"> On insulin or secretagogue Not on insulin or secretagogue 	7.1–8 < 8	5–8	< 12
Adult Frail and/or with Dementia (6-8) <ul style="list-style-type: none"> On insulin or secretagogue Not on insulin or secretagogue 	7.1–8.5 < 8.5	6–9	< 14
End of Life - Terminally Ill (9)	A1c not recommended. Avoid symptomatic hyperglycemia or any hypoglycemia.	Individualized	Individualized
Preconception and Pregnancy <ul style="list-style-type: none"> Preconception Pregnant, pre-existing diabetes Pregnant, GDM Labor & Delivery (L & D) 	$\leq 7\%$ or $\leq 6.5\%$ if safe $\leq 6.5\%$ or $\leq 6.1\%$ if safe -- --	4–7 < 5.3 < 5.3 4–7 thru L & D	5–10 or 5–8 < 6.7 (< 7.8 one hr. pc) < 6.7 (< 7.8 one hr. pc) 4–7 thru L & D
Pediatrics <ul style="list-style-type: none"> Type 2 age < 18 yrs Type 1 age < 18 yrs Type 1 age < 18 yrs with severe or excessive hypoglycemia or hypoglycemia unawareness 	$\leq 7\%$ $\leq 7.5\%$ Higher than target	4–7 6–10 Higher than target	5–10 5–10 No set targets
Hospitalized (Adults) <ul style="list-style-type: none"> Labor & Delivery Non-critically ill Critically ill Peri-operative CABG intraoperatively Acute coronary syndrome 		4–7 5–8 preprandial (random < 10.0) 6–10 5–10 5.5 + 11.1 7–10	
<ul style="list-style-type: none"> Source: Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018;42 (Suppl 1):S1-S325. Accessed May 2018. Secretagogues: sulfonylureas, meglitinides. CKD: chronic kidney disease. *These targets are guidelines. In all cases targets should be individualized. 			